[Form 4] Rocket Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

John Militello, an officer of Rocket Pharmaceuticals (RCKT), received 40,000 restricted stock units (RSUs) on 09/08/2025 that convert one-for-one to common stock at no cash price. After the award, he beneficially owns 95,924 shares of common stock. The RSUs vest with one-third becoming fully vested on 09/08/2026 and the remainder vesting in equal quarterly installments over the subsequent two years. The filing identifies Militello as Vice President of Finance, Treasurer and Principal Accounting Officer. The form reports a non-derivative acquisition and includes a legal signature by an attorney-in-fact.

Insights

Corporate Governance Expert

TL;DR: Standard executive equity award with multi-year vesting, aligning executive interests with shareholders.

The 40,000 RSU award to an executive officer is a routine compensation mechanism used to retain key personnel and align incentives. The one-third cliff after one year followed by quarterly vesting over two years creates multi-year retention pressure. The post-transaction beneficial ownership of 95,924 shares provides context on existing insider stake but does not alone indicate control.

Compensation Analyst

TL;DR: Award structure is time-based RSUs with no cash exercise, implying service-based compensation rather than performance pay.

The award is expressly described as RSUs that convert one-for-one to common stock at $0 price, confirming time-based equity rather than option compensation. Vesting terms (1/3 at one year, then quarterly over two years) are explicit and typical for mid-tier executive grants. The filing does not disclose grant-date fair value or total yearly grant program size.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Militello John

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	40,000	$0.00	--

Holdings After Transaction: Common Stock — 95,924 shares (Direct)

Footnotes (1)

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on September 8, 2026, with the remaining shares vesting in equal quarterly installments over the following two years.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Militello John

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NJ 08512

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	09/08/2025		A(2)		40,000	A	$0	95,924	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

2. Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on September 8, 2026, with the remaining shares vesting in equal quarterly installments over the following two years.

Remarks:

Vice President of Finance, Treasurer, Principal Accounting Officer

	/s/ Martin Wilson, as attorney-in-fact for John Militello	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.